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A new common region of virus integration, Evi11, has been identified in two retrovirally induced murine
myeloid leukemia cell lines, NFS107 and NFS78. By interspecific backcross analysis, it was shown that Evi11
is located at the distal end of mouse chromosome 4, in a region that shows homology with human 1p36. The
genes encoding the peripheral cannabinoid receptor (Cnr2) and a-L-fucosidase (Fuca1) were identified near the
integration site by using a novel exon trapping system. Cnr2 is suggested to be the target gene for viral
interference in Evi11, since proviruses are integrated in the first intron of Cnr2 and retroviral integrations alter
mRNA expression of Cnr2 in NFS107 and NFS78. In addition, proviral integrations were demonstrated within
the 3* untranslated region of Cnr2 in five independent newly derived CasBrM-MuLV (mouse murine leukemia
virus) tumors, CSL13, CSL14, CSL16, CSL27, and CSL97. The Cnr2 gene encodes a seven-transmembrane
G-protein-coupled receptor which is normally expressed in hematopoietic tissues. Our data suggest that the
peripheral cannabinoid receptor gene might be involved in leukemogenesis as a result of aberrant expression
of Cnr2 due to retroviral integration in Evi11.
The identification of common virus integration sites (VISs)
in retrovirally induced murine cancers has been proved suc-
cessful for isolating transforming genes from hematopoietic
malignancies and solid tumors (3, 30, 50). Cellular genes may
become aberrantly expressed following proviral integration,
through activation by viral promoter or enhancer sequences.
Alternatively, proviral integration within the protein-coding
region of a gene may result in the expression of an altered
product (50). Abnormal expression of a proto-oncogene may
provide the target cell with a growth abnormality and contrib-
ute to malignant transformation. A number of common VISs
have been identified in murine retrovirally induced hematopo-
etic malignancies. These VISs are frequently designated eco-
tropic VISs (Evi1 to Evi10), although other names have been
used as well (4, 9, 30, 31, 34, 37, 41). Leukemia development in
retrovirally induced leukemias is a multistep process which
usually takes more then 3 months (3, 30, 50). Thus, in a ret-
rovirally induced leukemia, one can predict more than one
common VIS, resulting in aberrant expression of multiple
genes. The frequency of a particular common VIS is usually
low, i.e., below 5%, indicating that several of different genes
may be responsible for retrovirus-mediated leukemogenesis in
mice (3, 30, 50).
From a number of primary hematopoietic tumors, induced
by Moloney murine leukemia virus (MoMuLV) or the wild
mouse ecotropic retrovirus CasBrM-MuLV, in vitro cell lines
have been established (3, 24). In these interleukin-3 (IL-3)-
dependent cell lines, several common VISs and potential on-
cogenes, including Evi1 (36), Evi2 (9), and His1 and His2 (4),
have been found. In the present study, we describe the iden-
tification of a new common VIS, designated Evi11, in two
myeloid leukemia cell lines and five newly isolated CasBrM-
MuLV-induced primary tumors.
Exon trapping has been used as an effective method for
deducing mRNA-coding sequences from genomic DNA
fragments (5, 10, 18, 23). We used a new exon trap vector,
pEVRF0-ET, based on the rabbit b-globin (RbG) gene, which,
in contrast to pSPL1 with an artificial intron (10), contains the
natural intervening sequence 2 of the RbG gene (IVS2-b).
This exon trap system was applied to the Evi11 locus, and two
genes, the peripheral cannabinoid receptor gene (Cnr2, for-
merly designated Cb2 [S2]) and the a-L-fucosidase gene
(Fuca1), were identified. The results of the studies presented
here suggest that the hematopoietic receptor gene Cnr2 is the
candidate gene for viral interference in Evi11.
MATERIALS AND METHODS
Cell lines. Nine leukemic cell lines established in vitro from CasBrM-MuLV-
induced primary tumors (NFS22, -36, -56, -58, -60, -61, -78, -107, and -124) (24)
and 13 cell lines derived from MoMuLV-induced tumors (DA1, -2, -3, -7, -8, -13,
-24, -25, -28, -29, -31, -33, and -34) (26) were cultured in RPMI 1640 medium
supplemented with penicillin (100 IU/ml), streptomycin (100 ng/ml), 10% fetal
calf serum (FCS), and 10% WEHI-3B cell conditioned medium (25). COS-1 cells
were cultured in Dulbecco’s modified Eagle’s medium (DMEM) containing 10%
FCS, penicillin, and streptomycin.
Primary tumors. Newborn NIH-Swiss mice were injected subcutaneous with
cell culture supernatant of CasBrM-MuLV-producing NIH 3T3 cells (obtained
from H. Morse III, National Cancer Institute, Frederick, Md.). Between 150 and
220 days after injection, the mice developed leukemias. All leukemic mice had
enlarged (5- to 10-fold) spleens, and some had thymomas. Sixty CasBrM-MuLV-
induced leukemias (CSL [CasBrM-MuLV Swiss leukemias]) were cryopreserved
* Corresponding author. Mailing address: Institute of Hematology,
Erasmus University Rotterdam, P.O. Box 1738, 3000 DR Rotterdam,
The Netherlands. Phone: 31104087843. Fax: 31104362315. E-mail:
Delwel@hema.fgg.eur.nl.
6796
in liquid nitrogen. From these tumors, high-molecular-weight DNA was isolated
(44) for Southern blot analysis.
Genomic cloning. From NFS107 cells, high-molecular-weight DNA was iso-
lated as described previously (44). The DNA was partially digested with Sau3A
and separated on 0.4% agarose. DNA fragments of 9 to 23 kb were isolated by
electroelution and purified on NACS columns (Bethesda Research Laboratories,
Bethesda, Md.). These fragments were then ligated into BamHI EMBL3 phage
arms and packaged (Stratagene, La Jolla, Calif.). DNA from 106 plaques was
transferred to nitrocellulose filters and screened (44) with a [32P]dATP-labelled
270-bp SmaI-PvuII fragment isolated from the U3 long terminal repeat (LTR) of
MoMuLV (15). Probes were labelled by random priming (19). Filters were
hybridized in 50% (vol/vol)–formamide–5% dextran sulfate sodium salt–53
SSPE (0.9 M NaCl, 0.05 M NaH2PO4 z H2O, 0.005 M EDTA [pH 7.7]–103
Denhardt’s solution (0.2% [wt/vol] bovine serum albumin, 0.2% [wt/vol] Ficoll
400, 0.2% [wt/vol] polyvinylpyrrolidone)–0.1% (wt/vol) sodium dodecyl sulfate
(SDS)–0.1 mg of sonicated salmon sperm DNA per ml. The blots were hybrid-
ized at 42°C overnight, washed for 15 min at 65°C in 23 SSPE–0.5% SDS and for
15 min at 65°C 0.53 SSPE, and analyzed by autoradiography. Phage DNA was
isolated (44), and restriction maps of the different clones were prepared. DNA
fragments adjacent to the VIS were isolated, subcloned in pBluescript II SK1
(Stratagene), and used for Southern blot analysis using DNAs of the different
DA and NFS cell lines. Cosmid clones were isolated from a female (4 to 8 weeks)
mouse liver genomic library (Stratagene catalog no. 946305) and a murine em-
bryonic stem cell genomic library in cosmid pTBE, using standard techniques
(44).
Southern and Northern blot analysis. Genomic DNA was isolated as de-
scribed previously (16), digested with the appropriate restriction enzymes, and
electrophoresed on a 0.6% agarose gel. Fragments were transferred to Hy-
bond-N1 (Amersham) nylon membranes with 0.25 M NaOH–1.5 M NaCl. Total
RNA from cell lines was extracted with guanidinium isothiocyanate as described
previously (44). Ten micrograms of total RNA was separated on a 1% aga-
rose–6% formaldehyde gel and blotted with 203 SSC (13 SSC is 0.15 M NaCl
plus 0.015 M sodium citrate) onto Hybond-N1 nylon membranes (Amersham).
Hybridization and washing procedures for Northern and Southern blots were
identical to those described above. mRNA hybridization signals were quantitated
by scanning of the Northern blots with a Vilber Lourmat camera and Bio-Profil
V 4.6 software.
RNase protection. RNase protection was performed as described previously
(44). Fragments were cloned into pBluescript II SK1 and linearized by using the
proper enzymes, and RNA probes were synthesized by using T3 or T7 polymer-
ase. For each incubation, 10 mg of RNA and radiolabelled RNA probe (15,000
cpm) was suspended in 30 ml of hybridization buffer [80% deionized formamide,
40 mM piperazine-N,N9-bis(2-ethanesulfonic acid) (PIPES; pH 6.4), 0.4 M so-
dium acetate, 1 mM EDTA]. The samples were heated to 85°C for 5 min and
then incubated for 16 h at an annealing temperature of 50°C. To these mixtures,
300 ml of RNase digestion buffer (10 mM Tris-HCl [pH 7.5], 5 mM EDTA, 200
mM sodium acetate) and 1 U of RNase One (Promega, Leiden, The Nether-
lands) were added. After 1 h at 37°C, the reaction was stopped by the addition
of 3.3 ml of 10% SDS and 20 mg of carrier tRNA. The reaction products were
precipitated with ethanol, fractionated by electrophoresis in a 6% polyacryl-
amide–7 M urea gel, and analyzed by autoradiography. A radiolabelled GAPDH
RNA fragment was used as a control (28).
Interspecific backcross mapping. Interspecific backcross progeny were gener-
ated by mating (C57BL/6J 3 Mus spretus)F1 females and C57BL/6J males as
described previously (14). A total of 205 backcross mice were used to map the
l6.2 locus (see Results for details). DNA isolation, restriction enzyme digestion,
agarose gel electrophoresis, Southern blot transfer, and hybridization were per-
formed essentially as described elsewhere (29). All blots were prepared with
Hybond-N1 nylon membrane (Amersham). The probe, a 1.2-kb SalI/SstI frag-
ment of mouse genomic DNA, was labelled with [a-32P]dCTP by using a random
prime labelling kit (Amersham); washing was done to a final stringency of 0.83
SSCP–0.1% SDS at 65°C. A 10.5-kb fragment was detected in HincII-digested
C57BL/6J DNA, while 6.2- and 4.0-kb fragments were detected in M. spretus
DNA. The presence or absence of the 6.2- and 4.0-kb M. spretus-specific HincII
fragments, which cosegregated, were followed in backcross mice. The probes and
restriction fragment length polymorphisms for the loci linked to the Evi11 locus,
including the Gardner-Rasheed feline sarcoma viral oncogene homolog (Fgr)
and natriuretic peptide precursor type A gene (Nppa), have been described
previously (11). Recombination distances were calculated as described by Green
(22), using the computer program SPRETUS MADNESS. Gene order was
determined by minimizing the number of double and multiple recombination
events across the chromosome.
Exon trapping. The exon trap vector was based on a eukaryotic expression
vector pEVRF0, which had been designed for the analysis of mutant proteins
(38). The vector contains pSP65 bacterial plasmid sequences, the human cyto-
megalovirus enhancer/promoter, the translation initiation region from the herpes
simplex virus thymidine kinase gene, splicing and polyadenylation signals from
the RbG gene, and the simian virus 40 origin of replication (46) (see Fig. 4A).
The RbG fragment includes map position 905 (BamHI) to position 2080 of the
RbG gene. This fragment consists of IVS2-b flanked by thymidine kinase-RbG
exon 2 and RbG exon 3. A 39-bp SmaI/HincII fragment from the polylinker of
pBluescript II SK1 was cloned into the HincII site of the IVS2-b to introduce
multiple cloning sites. Genomic DNA from cosmids 5 and 10 (see Fig. 2A) were
partially digested with HpaII and separated on a 1% agarose gel, and fragments
of between 2 and 5 kb were isolated. These HpaII fragments were ligated in the
newly created ClaI site. COS cells were grown to 650% confluency. DEAE-
dextran (100 mg/ml) and 10 mg DNA in DMEM were added; after 2 h, this
solution was replaced by 0.1 mM chloroquine in DMEM. Cells were incubated
with this mixture for 3 h, and then the medium was refreshed by DMEM with
10% FCS. The cells were cultured for 2 to 3 days, and total RNA was isolated.
Reverse transcriptase (RT)-PCR was carried out with primers 1A
(59-GGGGGATCTTGGTGGCGTG-39) and 1B (59-AGATCTCAGTGGTATT
TGTGAGC39). Subsequently, a nested PCR was performed with primers 2A
(59-CGTCTAGAGGAGTGAATTCTTTGC-39) and 2B (59-ATCCATGGAT
CCTGAGAACTTCAG-39). The PCR cycling conditions were as follows: for
primers set 1A-1B, 1 min at 94°C, 1 min at 64°C, and 1 min at 72°C (30 cycles);
for primer set 2A-2B, 1 min at 94°C, 1 min at 52°C, and 1 min at 72°C (30 cycles).
Amplified fragments were visualized on a 2% agarose gel by ethidium bromide
staining. Potential exons were subcloned into pBluescript II SK1 by digestion
with BamHI/EcoRI (see Fig. 4A). Border sequences of RbG exon 2 and RbG
exon 3 were thereby included in the cloned product.
Sequence analysis. Nucleotide sequencing was performed by the method of
Sanger and Coulsen (45). Fragments were cloned into pBluescript II SK1 and
sequenced with T3, T7, or sequence-specific primers. Deduced sequences were
analyzed by using the BLAST network service of the National Center for Bio-
technology Information.
RT-PCR. RT reactions were performed for 1.5 h at 37°C with 3 mg of total
RNA in 50 mM Tris-HCl (pH 8.3)–75 mM KCl–3 mM MgCl2–1 mM dithiothre-
itol–40 mM oligo(dT)16–0.5 mM deoxynucleoside triphosphates–1 U of RNA-
guard (Pharmacia)–100 U of SuperScript RT (Gibco, Breda, The Netherlands).
The PCR mixture contained 10 mM Tris-HCl (pH 8.3), 50 mM KCl, 1.5 mM
MgCl2, 150 mM deoxynucleoside triphosphates, and 2.5 U of Taq polymerase.
PCR cycling started with 10 min at 94°C and ended with a 10-min extension at
72°C.
cDNA cloning by PCR. All RT reactions for the RACE (rapid amplification of
cDNA ends) experiments were done with 2 mg of poly(A)1 RNA. Poly(A)1
RNA was purified by affinity chromatography using oligo(dT)-cellulose columns
(Pharmacia). 39 RACE experiments were performed by using an oligo(dT)
adapter primer [59-GTCGCGAATTCGTCGACGCG(dT)15-39] for first-strand
synthesis. Subsequently, PCR was carried out with the adapter primer
(59-GTCGCGAATTCGTCGACGCG-39) in combination with gene-specific
primers (CBR15 [59-CACGCTTAGTGATTTAGACT-39; bp 2634 to 2653] and
CBR16 [59-GTATTTCAACATCAACTTGG-39; bp 2654 to 2673]). Cycling pa-
rameters were 1 min at 94°C, 2 min at 57°C, and 3 min at 72°C (25 cycles).
Products were cloned into pBluescript II SK1 and sequenced. A 59-Ampli-
FINDER RACE kit (Clontech, Palo Alto, Calif.) was used to isolate additional
59 cDNA sequences. The strategy for the 59 RACE was as follows. A gene-
specific primer (CBR3 [59-GTGAAGGTCATGGTCACACT-39; bp 517 to 536])
was used for first-strand synthesis, and then an anchor primer was ligated to the
cDNA 39 end. Subsequently, the anchor primer and nested primers (CBR9
[59-CCGTTGGTCACTTCTGTCTC-39; bp 199 to 218] and CBR10 [59-GAGC
TGTCCAGAAGACTGGG-39; bp 138 to 158]) were used to amplify additional
59 cDNA fragments. Cycling parameters for both primer sets were 1 min at 94°C,
1 min at 57°C, and 3 min at 72°C (25 cycles). The products that were obtained by
59 RACE were cloned into pBluescript II SK1 and sequenced.
Nucleotide sequence accession number. The accession number for the murine
Cnr2 sequence is X93168.
RESULTS
Identification of a common integration site (Evi11) in cell
lines NFS107 and NFS78. A Sau3A partial genomic library
from NFS107 was prepared in EMBL3. The library was
screened with a specific U3 LTR probe from MoMuLV (15),
and eight different LTR-positive clones were obtained (data
not shown). The restriction map of one clone, l6.2, is shown in
Fig. 1A. From this phage clone, a nonviral, nonrepetitive
1.2-kb SstI/SalI probe F (Fig. 1A) was isolated and used for
further analysis. With this probe, DNAs from 13 MoMuLV-
and 9 CasBrM-MuLV-induced leukemic cell lines were
screened by Southern analysis using the restriction enzymes
PvuII, SstI, XbaI, KpnI, PstI, and HindIII. As shown in Fig. 1B,
rearrangements were identified in NFS107 and in the leukemic
cell line NFS78. Southern analysis also revealed that NFS78
had lost its normal allele (Fig. 1B, SstI, KpnI, PstI, and
HindIII). NFS107 and NFS78 are both IL-3 dependent and do
not respond to granulocyte and granulocyte-macrophage col-
ony-stimulatory factors (G-CSF and GM-CSF), stem cell fac-
tor, and IL-7 (data not shown). NFS107 cells express the my-
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eloid markers myeloperoxidase, Mac-1, and Mac-2 (27).
NFS78 is a leukemic cell line with myeloblastic characteristics
(24) and expresses the myeloid marker Mac-1 (27). Immuno-
globulin heavy-chain genes of both cell lines are in germ line
configuration. Southern blotting and genetic backcross analysis
with a fragment derived from another integration site in
NFS107 demonstrated that this integration had occurred in the
recently identified common VIS, Evi3 (data not shown and
reference 31). NFS78 expresses another common VIS, Evi1
(36). NFS22 (Fig. 1B) and 19 other cell lines did not show
rearrangements in the Evi11 locus after hybridization with
probe E, F, or C (Fig. 2B). To obtain genomic DNA of the
normal Evi11 locus, two genomic cosmid libraries were
screened with probe F (Fig. 1A and 2B). We isolated three
cosmid clones, 32B, 5, and 10, covering a region of approxi-
mately 70 kb of the locus that we designated Evi11. A limited
restriction map of Evi11 is shown in Fig. 2A. The orientation of
the viral DNA in NFS107 and NFS78 was deduced from re-
striction enzyme analysis of the normal genomic organization
(cosmids 5 and 32B) and Fig. 1B, in combination with the
restriction map of CasBrM-MuLV (accession no. X57540). In
NFS78, retroviral DNA is oriented opposite the integrated
viral DNA within the same locus in NFS107 (Fig. 2A). The
distance between the two integrations is approximately 3 kb.
Chromosomal localization of Evi11. The chromosomal lo-
calization of Evi11 was initially determined to be on murine
chromosome 4 by fluorescence in situ hybridization (FISH)
analysis (data not shown). A more exact positioning of Evi11
was obtained by interspecific backcross analysis using progeny
derived from matings of [(C57BL/6J 3 M. spretus)F1 3
C57BL/6J] mice. This interspecific backcross mapping panel
has been typed for over 2,100 loci that are well distributed
among all mouse autosomes and the X chromosome (14, 14a).
C57BL/6J and M. spretus DNAs were digested with several
restriction enzymes and analyzed by Southern blot hybridiza-
tion for informative restriction fragment length polymor-
phisms, using the mouse 1.2-kb SstI/SalI probe F (Fig. 1A).
Cosegregating 6.2- and 4.0-kb M. spretus-specific HincII frag-
ments were used to monitor the segregation of the Evi11 locus
in backcross DNAs. The mapping results indicated that Evi11
is located in the distal region of mouse chromosome 4 (Fig. 3).
Although 117 mice were analyzed for all three markers shown
in the haplotype analysis (Fig. 3), up to 121 mice could be
typed for one pair of markers. Each locus was analyzed in
pairwise combinations for recombination frequencies, using
FIG. 1. Identification of common integration site Evi11. (A) Restriction en-
zyme map of virus integration site l6.2 [SI, SalI; S, SstI; H, HindIII; P, PstI; (SI),
SalI from EMBL3 phage arms]. (B) Rearrangement of the Evi11 locus by South-
ern blot analysis of genomic DNA from retrovirus-induced murine leukemia cell
lines NFS22, NFS78, and NFS107. Filters were hybridized to a 1.2-kb fragment
(probe F) from the l6.2 integration site. Sizes are indicated in kilobases.
FIG. 2. Restriction enzyme map and genomic structure of Evi11. (A) Restriction pattern of Evi11 based on Southern analysis with cosmid clones 5, 10, and 32B
(N, NotI; SI, SalI; E, EcoRI; S, SstI; H, HindIII; P, PstI). The locations of the trapped Cnr2 fragment (Cnr2) and exon 3 of Fuca1 (Fuca1) are indicated. Arrows indicate
the locations and orientations of provirus in NFS78 and NFS107 as well as CSL13, CSL14, CSL16, CSL27, and CSL97. (B) Genomic structure of the Evi11 locus. The
location of the 59 noncoding exon 1 and protein-coding exon 2 of Cnr2, the 59 exon of a-L-fucosidase, and probes E, F, and C are depicted diagrammatically, with
notation corresponding to that in panel A.
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the additional data. The ratios of the total number of mice
exhibiting recombinant chromosomes to the total number of
mice analyzed for each pair of loci and the most likely gene
order are centromere-Fgr-2/121-Evi11-5/119-Nppa. The re-
combination frequencies (expressed as genetic distances in
centimorgans 6 the standard error) are centromere-Fgr-1.7 6
1.2-Evi11-4.2 6 1.8-Nppa. No recombinations were observed
between Evi11 and the a-L-fucosidase gene. The distal half of
mouse chromosome 4 shares a region of homology with human
chromosome 1 (Fig. 3).
Identification of transcribed sequences in the Evi11 locus by
using exon trapping. To isolate coding sequences from the
Evi11 locus, an exon trapping system was designed (Fig. 4A)
and applied to cosmid clones 5 and 10 (Fig. 2A). Partially
HpaII-digested fragments of cosmids 5 and 10, between 2 and
5 kb, were cloned into the ClaI site of the exon trap vector.
These constructs were pooled in groups of six clones per COS
cell transfection. Thirty transfections were performed. RT-
PCR was carried out on RNA isolated from the transfected
COS cells. Potential exons with sizes ranging from 50 to 300 bp
were amplified from the different pools, using primer set
1A-1B followed by 2A-2B, and visualized by ethidium bromide
staining. Eight examples of COS cell transfections are shown in
Fig. 4B (lanes 1 to 8). Transfection of the exon trap vector
without insert resulted in the isolation of a 97-bp fragment
representing the fusion of exons 2 and 3 of the RbG gene (Fig.
4B, lane V). Potential exons were subcloned into BamHI/
EcoRI-digested (Fig. 4A) pBluescript II SK1 and sequenced.
The DNA sequences were compared to those in the National
Center for Biotechnology Information database. Among 16
clones analyzed, one exon was the mouse homolog of exon 3 of
human FUCA1 (32), a gene which by interspecific backcrossing
had been shown to be located near Evi11 (Fig. 3). Seven clones
contained sequences that were homologous to part of the cod-
ing region of human CNR2 (39). However, the Cnr2 fragments
were trapped between the two RbG exons in the reversed
transcriptional orientation. Sequence analysis of these trapped
fragments and of the human cDNA of CNR2 demonstrated the
presence of cryptic splice sites at the proper positions in the
reversed orientation (see Fig. 6A). Eight clones contained cos-
mid vector sequences. The trapped fragments were radiola-
belled and used for Northern analysis to examine the expres-
sion of the representing genes in the different cell lines. Two
different mRNAs, of 61.6 and 64.0 kb, were identified (Fig.
5). Analysis using separate probes revealed that the 61.6-kb
signal represented a-L-fucosidase, and the Cnr2 fragment de-
tected the 64.0-kb mRNA. In NFS78, NFS107, and control
cell lines NFS22 and NFS36, variable levels of Cnr2 mRNA
were apparent (Fig. 5). In NFS78, Cnr2 mRNA levels were
higher than in control cell lines, whereas in NFS107, no Cnr2
mRNA could be identified (Fig. 5 and Table 1). In fact, North-
ern analysis using RNAs from a panel of cell lines demon-
strated variable levels of Cnr2 mRNA expression in all DA and
NFS lines (data not shown). Levels of Fuca1 transcripts in the
different cell lines were comparable (Fig. 5, Table 1, and data
not shown). Although the levels of Fuca1 mRNA in the dif-
ferent leukemic cell lines (Table 1 and data not shown) were
less variable than the Cnr2 mRNA levels, the Northern analysis
was not conclusive with respect to altered gene expression
caused by virus integration.
The Cnr2 nucleotide sequence and exon structure. Southern
blot analysis was carried out on the three Evi11 cosmid clones
FIG. 3. Evi11 maps in the distal region of mouse chromosome 4. Evi11 was
mapped to mouse chromosome 4 by interspecific backcross analysis. The segre-
gation patterns of Evi11 and flanking genes in 117 backcross animals are shown
at the top. For some of the individual pairs of loci, more than 117 animals were
typed (see text). Each column represents the chromosome identified in the
backcross progeny that was inherited from the (C57BL/6J 3 M. spretus)F1 par-
ent. The shaded boxes represent the presence of a M. spretus allele. The number
of offspring inheriting each type of chromosome is listed below each column. A
partial chromosome 4 linkage map showing the location of Evi11 in relation to
linked genes is shown at the bottom. Recombination distances between loci in
centimorgans are shown to the left of the chromosome, and the positions of loci
in human chromosomes are shown to the right. References for human map
positions can be obtained from GDB, a computerized database of human linkage
information maintained by The William H. Welch Medical Library of The Johns
Hopkins University (Baltimore, Md.).
FIG. 4. Isolation of transcribed sequences from Evi11 by exon trapping. (A)
Exon trap vector pERVF0. Abbreviations not given in the text: SV40, simian
virus 40 origin of replication; CMV, human cytomegalovirus enhancer/promoter
region; TK, thymidine kinase translation initiation region; E2 and E3, exon 2 and
exon 3 of the RbB gene; MCS, multiple cloning site (BamHI [B], ClaI [C], EcoRI
[E], HincII [H], SmaI [Sm], and primers 1A, 1B, 2A, and 2B). (B) Agarose gel
electrophoresis of RT-PCR fragments (primers 2A and 2B) obtained from
COS-1 cells transfected with the exon trap vector pERVF0. Lanes 1 to 8,
ethidium bromide stainings of RT-PCR fragments obtained from transfections
with pERVF0 containing Evi11 genomic inserts; lane V, RT-PCR fragment from
a transfection with empty vector; lane C, RT-PCR using RNA from nontrans-
fected COS cells; M, 1-kb ladder (Boehringer).
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to determine the positions of the amplified fragments (Fig.
2A). The trapped Cnr2 fragment was mapped on a 3-kb EcoRI/
EcoRI fragment (Fig. 2). The localization was confirmed by the
presence of a relatively rare SalI site in this fragment. a-L-
Fucosidase exon 3 is situated approximately 12 kb from the
provirus in NFS78. Since Cnr2 is located nearer the VIS than
the a-L-fucosidase gene, and the gene encodes a hematopoietic
receptor (39), which may be involved in monocyte/macrophage
differentiation (40), we decided to determine the nucleotide
sequence and genomic structure of Cnr2. Southern analysis
with 59 and 39 cDNA probes of the human CNR2 gene sug-
gested that the entire protein-coding sequence was located
within the 3-kb EcoRI/EcoRI fragment (Fig. 2). HpaII and
Sau3A fragments of the 3-kb EcoRI/EcoRI fragment were
subcloned into, respectively, the ClaI and BamHI sites of
pBluescript II SK1 and sequenced (Fig. 6A). The merged
nucleotide sequences of the 3-kb EcoRI/EcoRI fragment
showed that the complete protein-coding sequence of the mu-
rine Cnr2 receptor is present within this 3-kb fragment. The
amino acid sequence of the murine Cnr2 gene product is 82%
homologous to that of the human CNR2 gene product. The
C-terminal end of the murine homolog lacks nine amino acids.
An amino acid sequence comparison of murine Cnr2, human
CNR2 (39), and murine (accession no. U22948) and human
(CNR1 [21]) brain cannabinoid receptor 1 gene products is
shown in Fig. 6B. Nucleotide sequencing of the Cnr2 protein-
coding region from NFS107 and NFS78 cDNA did not show
any mutations. The 39 noncoding sequence was isolated by 39
RACE on poly(A)1 from control cell line NFS22 by using two
gene-specific primers (CBR15 and CBR16). Two fragments,
which terminated at bp 2951 and 3756, were isolated. The 39
untranslated regions (UTRs) appeared to be, respectively,
1,724 and 2,528 bp long, with putative polyadenylation signals
(AAUAAA) at bp 2928 and 3743. This variability in 39 UTR
lengths has also been shown for the rat brain cannabinoid
receptor (35). The Cnr2 sequence identified so far is located in
one exon. Upstream of the ATG start site of mouse Cnr2 on
the 3-kb EcoRI/EcoRI fragment, a potential 39 splice acceptor
site was identified (Fig. 7A). To investigate whether 59 exons,
which could splice to this potential acceptor site, existed, 59
RACE was carried out using poly(A)1 RNA from the control
cell line NFS22. Amplification with the anchor primer and
CBR9, followed by a nested PCR with the anchor primer and
CBR10, resulted in the isolation of a fragment of 179 bp (Fig.
6A). This fragment was cloned into pBluescript II SK1, and
sequence analysis revealed that an exon of at least 121 bp was
spliced to the predicted splice acceptor site. Since this exon
introduces a stop codon in frame with the ATG start site, this
exon is noncoding (Fig. 6A). Interestingly, Southern blot anal-
FIG. 5. Expression of Cnr2 and Fuca1 in retrovirally induced leukemias,
determined by Northern analysis of NFS22, NFS36, NFS78, and NFS107. Total
RNA was hybridized to a 32P-labelled Fuca1 exon 3 probe and a 32P-labelled
Cnr2 fragment which had been obtained by exon trapping. The filter was subse-
quently hybridized with a 32P-labelled GAPDH probe (28).
FIG. 6. Nucleotide and protein sequences of the mouse and human canna-
binoid receptors. (A) Nucleotide and deduced protein sequences of mouse Cnr2.
In-frame stop codons in the 59 and 39 UTRs and 59 RACE primers CBR9 (bp 199
to 218) and CBR10 (bp 138 to 158) are underlined. The splice site of Cnr2 is
indicated by an arrow. Exon 1 of NFS78 is italicized. The cryptic splice sites
located on the noncoding strand are double underlined. (B) Amino acid com-
parison of the murine Cnr2 (MCB2), human CNR2 (HCB2), mouse Cnr1
(MCB1) and human CNR1 (HCB1) gene products. Identities are on a black
background, similarities are on a gray background, and the seven transmembrane
domains are underlined.
TABLE 1. Cnr2 and Fuca1 mRNA levels in NFS cell lines
mRNAa
Level (% of GAPDH control)
NFS22 NFS36 NFS78 NFS107
Fuca1 15 12 18 7
Cnr2 10 4 36 0
a Identified by Northern blot analysis (Fig. 5).
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ysis demonstrated that exon 1 of Cnr2 is located approximately
20 kb upstream of protein-coding exon 2. Thus, virus integra-
tions in NFS107 and NFS78 have occurred in an intron of Cnr2
(Fig. 7A).
Cnr2 expression in leukemic cell lines. Northern analysis
demonstrated variable levels of Cnr2 mRNA expression in the
distinct cell lines studied (Fig. 5, Table 1, and data not shown)
but was not conclusive with respect to the viral integrations.
Since in NFS78 and NFS107, proviral DNA is integrated in the
Cnr2 intron, we verified with RNase protection whether the
levels of expression of the two exons had been altered. A
195-bp EcoRI (anchor 59 RACE)/NcoI fragment overlapping
Cnr2 exons 1 and 2 (Fig. 7A) was generated to protect both
exons with RNase protection. RNase protection analysis
revealed variable levels of full-length Cnr2 mRNA in the
control cell lines (NFS36, NFS56, NFS58, NFS61, and
NFS124) (Fig. 7B, 187 bp [exon 1 1 2]). In NFS107, full-
length Cnr2 as well as 137-bp transcripts, representing exon
1, were detected. Thus, although no Cnr2 transcripts could
be detected in NFS107 by Northern blot analysis, Cnr2
mRNA was demonstrated by using the more sensitive
RNase protection technique. In NFS78, full-length Cnr2
mRNA could not be demonstrated; however, a 50-bp frag-
ment which corresponds to exon 2 mRNA was protected.
This finding is in agreement with the Southern blot analysis
(Fig. 1B), showing a normal and rearranged allele in
NFS107 and only an abnormal allele in NFS78. 59 RACE
carried out on poly(A)1 RNA of NFS78 resulted in frag-
ments of different sizes. Sequencing (Fig. 6A) showed that
in this cell line, another noncoding exon located down-
stream of provirus DNA was fused to the splice acceptor site
of exon 2 of Cnr2 (Fig. 7A). In an assay using a 680-bp probe
specific for exons 19 and 2 (Fig. 7A), two large fragments
(600 and 430 bp) were protected in NFS78 only (Fig. 7C).
The 600-bp band represents the complete exon 19-plus-2
transcript, whereas the smaller band corresponds with a part
of exon 19 fused to exon 2. In the other cell lines, a band of
350 bp which represents exon 2 only is protected. Thus, the
RNase protection analysis demonstrate altered aberrant
Cnr2 mRNA expression in both NFS107 and NFS78.
Evi11 in CasBrM-MuLV-induced primary tumors. To de-
termine the frequency of Evi11/Cnr2 retroviral insertions,
Southern blot analysis was carried out with probe E, F, or C
(Fig. 2B) and different restriction enzymes on high-molecular-
weight DNA isolated from CasBrM-MuLV-induced splenic
tumors. Interestingly, DNA rearrangements were observed
within the Evi11 locus in five cases, i.e., CSL13, CSL14, CSL16,
CSL27, and CSL97, using probe C (Fig. 8), which corresponds
to the protein-coding region of Cnr2 (Fig. 2B). No rearrange-
ments were detected in control primary tumors, e.g., CSL103
and CSL12. From the Southern blot analysis of DNA digested
with multiple enzymes (SstI, PstI, and BamHI), it was con-
cluded that retroviral integrations in Evi11 had occurred within
the 39 UTR of Cnr2 in the same transcriptional orientation
(Fig. 2B). The locations and orientations of the proviruses
were confirmed by PCR analysis using Cnr2- and MuLV LTR-
specific primers (data not shown).
FIG. 6—Continued.
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DISCUSSION
Neoplasias induced by retroviruses that lack dominant-act-
ing oncogenes have been shown to depend on proviral inte-
grations into particular loci of the cellular genome (3, 30, 50).
Integration of viral DNA independently in the same locus in
different tumors might indicate loci that have a functional role
in the multistep process of malignant transformation. In two
murine IL-3-dependent myeloid leukemia cell lines (24), i.e.,
NFS107 and NFS78, and five primary tumors, i.e., CSL13,
CSL14, CSL16, CSL27, and CSL97, induced in CasBrM-
MuLV-infected NFS/N mice, a new common virus integration
site, Evi11, was identified and cloned. NFS107 was initially
chosen for this study because of the absence of rearrangements
in loci of several known proto-oncogenes (27). Interestingly,
however, among eight integration sites that we isolated from
NFS107, one represented the recently identified common VIS
Evi3 (data not shown and reference 31). This finding might
suggest that alterations in the expression of the Evi11 and an
Evi3 proto-oncogene synergize to generate a malignantly trans-
formed myeloid cell. Likewise, in NFS78 leukemia cells, pro-
virus is integrated in the Evi1 locus (36), which may suggest
that aberrant expression of an Evi11 proto-oncogene and Evi1
cooperated in the development of the latter myeloid leukemia.
Cooperation of genes involved in the initiation and/or progres-
sion of hematopoietic tumors has been shown by others (30,
41).
To isolate genes located near the VIS, we established an
exon trapping/amplification system based on the expression
vector pEVRF0 (38). This exon trap vector is related to the
pSPL1-vector (10), which also uses the RbG gene exons 2 and
3. The main difference between pEVRF0 and pSPL1 is that the
natural intervening sequence, IVS2-b, is used in pERVF0,
whereas in pSPL1, IVS2-b is replaced by the human immuno-
deficiency virus tat intron. Thus, by using pERVF0, we wished
to avoid the possibility of isolating false positives caused by a
cryptic splice site present within the tat intron sequence (13,
42). With the novel exon trapping system, we identified two
genes in Evi11. The a-L-fucosidase exon that was trapped is the
mouse homolog of exon 3 of human FUCA1 (20). The second
fragment that was isolated from the Evi11 locus encodes part
of the murine cannabinoid receptor 2, based on a strong ho-
mology to human CNR2 (39) and identity to the recently
cloned mouse Cnr2 (48). The isolated fragment of Cnr2 was
trapped in the incorrect transcriptional orientation because of
the presence of cryptic 59 and 39 splice sites on the noncoding
strand (Fig. 6A). Thus, although apparently exons can be iso-
lated efficiently by using pERVF0, it is also clear that false
positives may be isolated by using exon trapping procedures.
Since sequences derived from the cosmid vector were also
trapped, it appears useful to eliminate vector DNA before
cloning genomic DNA into the pERVF0 vector.
Two genes, Fuca1 and Cnr2, were identified in the Evi11
locus. The data suggest that Cnr2 is the candidate target gene,
since provirus is integrated in the Cnr2 intron in NFS78 and
NFS107, and although the mechanism needs further study,
virus integrations in this locus lead to aberrant Cnr2 mRNA
expression in NFS78 and NFS107. In addition, all proviral
integrations identified in the CasBrM-MuLV-induced primary
FIG. 7. Cnr2 is aberrantly expressed in the murine myeloid leukemia cell
lines NFS78 and NFS107. (A) Genomic organization of mouse Cnr2. The shaded
box represents the open reading frame. The sites of proviral integration as well
as the orientation are shown by arrows. Exon 19 is the alternative exon which is
fused to exon 2 in NFS78. The fragments and restriction sites used to generate
RNA probes for RNase protection experiments are indicated [E, EcoRI; N, NotI;
Nc, NcoI; SI, SalI; (E), EcoRI site in anchor primer 59 RACE]. (B) RNase
protection on 10 mg of total RNA of a series leukemic cell lines, using an exon
1- and 2-specific probe (A). The full-length Cnr2 protected fragment was 187 bp
(exon 1 [137 bp] and exon 2 [50 bp]). (C) RNase protection on 10 mg of total
RNA of a series leukemic cell lines, using an exon 19- and 2-specific probe (A).
The full-length protected fragment was 600 bp (exon 19 [250 bp] and exon 2 [350
bp]). Another fragment of approximately 430 bp represents part of exon 19 plus
exon 2.
FIG. 8. Proviral integrations within the 39 UTR of the Cnr2 gene, determined
by Southern blot analysis with probe C (Fig. 2B) on PstI and SstI-digested
genomic DNA from CasBrM-MuLV-induced primary tumors. The locations and
orientations of the retroviruses in Evi11 are depicted in Fig. 2B.
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tumors reside within the 39 UTR of Cnr2. These integrations
resemble classical proviral integrations which generally en-
hance expression of the target gene (3, 30, 50). However, the
possibility remains that another gene within the Evi11 locus is
affected due to retroviral insertion.
Cnr2 encodes a hematopoietic receptor that belongs to the
class of seven-transmembrane G-protein-coupled receptors.
Cnr2 consists of a small 59 noncoding exon 1 and a large exon
2 that contains the complete protein-coding region. Interest-
ingly, small 59 noncoding exons have been identified in a series
of genes that encode G-protein-coupled receptors, e.g., the
Burkitt’s lymphoma receptor 1 gene (BLR1) (17), the mas
oncogene-related rat thoracic aorta receptor gene (RTA) (43),
and recently also CNR1 (47). This could suggest that the small
59 exons are important in regulation of gene expression. In
NFS78 and NFS107 cells, proviruses are integrated in the in-
tron that separates exon 1 from exon 2. Our data indicate
abnormal expression of Cnr2 exon 1 in NFS107 and NFS78.
The RNase protection data are indicative of an mRNA in
NFS107 that contains exon 1 only. This deleted transcript is
probably the result of the polyadenylation signal introduced by
the LTR of the provirus that is integrated in the proper ori-
entation downstream of exon 1 (Fig. 7A). In NFS78, exon 1 is
absent and an alternative exon is fused to the protein-coding
exon 2 (Fig. 6A and 7A). If aberrant mRNA expression of exon
1 as the result of proviral integration leads to abnormal levels
of Cnr2 receptors and contributes to leukemic transformation,
this would suggest that exon 1 contains important regulatory
sequences. We are currently raising antibodies to examine the
levels of Cnr2 receptors in NFS78, NFS107, and control cell
lines.
Interestingly, RNase protection experiments have demon-
strated that Cnr2 may be expressed in most hematopoietic
lineages and that the ligand for cannabinoid receptors, anan-
damide, synergistically stimulates proliferation of hematopoi-
etic progenitor cell lines with cytokines, e.g. IL-3, GM-CSF,
erythropoietin, and G-CSF (52). Thus, Cnr2 appears to encode
an important hematopoietic receptor which following activa-
tion enhances the response to hematopoietic growth factors.
This finding adds further support to the hypothesis that this
receptor, when aberrantly expressed, may alter the prolifera-
tive response of hematopoietic cells and contribute to the
development of leukemia. Several other genes that encode
G-protein-coupled receptors have been implicated in onco-
genic transformation (1, 49, 53, 54).
FISH analysis and interspecific backcrossing demonstrated
that Evi11 is located on the distal end of murine chromosome
4. This locus is distinct from known proto-oncogenes and com-
mon viral integration loci previously identified in the mouse.
This particular region on murine chromosome 4 is homologous
to a region on human chromosome 1p, i.e., 1p36. Evi11 was
found to localize between two genes, Fgr and Nppa. These
comparative mapping results suggest that FUCA1 and CNR2
map to human 1p36 as well. In fact, it had already been shown
that human FUCA1 resides on chromosome 1p36 (20). FISH
analysis using a human CNR2 cDNA probe indeed demon-
strated that this gene is also located on 1p36 in humans (data
not shown). 1p36 is involved in breakpoints in certain cases of
acute myeloid leukemia and myelodysplastic syndrome (7, 51)
but also in other malignancies, e.g., neuroblastomas (6, 12, 33).
This finding raises the question as to whether the human Evi11
locus and possibly CNR2 are mutated and aberrantly expressed
in certain human diseases with 1p36 abnormalities.
ACKNOWLEDGMENTS
We thank E. M. E. Smit (Department of Genetics, Erasmus Uni-
versity Rotterdam) for carrying out FISH analysis, S. E. Verbakel for
the assistance in cell culture experiments, M. Boschman and K. van
Rooyen for preparation of the figures, S. Munro (MRC Laboratory of
Molecular Biology, Cambridge, England) for providing the human
CNR2 cDNA, I. D. Hickson (Imperial Cancer Research Fund Labo-
ratories, University of Oxford, Oxford, England) for the GAPDH
RNase protection probe, and H. Morse III (NCI, Frederick, Md.) for
the donation of the CasBrM-MuLV-producing NIH 3T3 cells. D.
Meyer (Department of Genetics, Erasmus University Rotterdam) is
acknowledged for his advice on the construction of the exon trap
vector.
This work was supported by the Dutch Cancer Society Koningin
Wilhelmina Fonds, the Netherlands Organisation for Scientific Re-
search, and the Netherlands Academy of Sciences. This research was
sponsored in part by the National Cancer Institute under contract with
ABL.
REFERENCES
1. Allen, L. F., R. J. Lefkowitz, M. G. Caron, and S. Cotecchia. 1991. G-protein-
coupled receptor genes as protooncogenes: constitutively activating muta-
tion of the alpha1B-adrenergic receptor enhances mitogenesis and tumori-
genicity. Proc. Natl. Acad. Sci. USA 88:11354–11358.
2. Arata, S., C. Newton, T. Klein, and H. Friedman. 1992. Enhanced growth of
Legionella pneumophila in tetrahydrocannabinol-treated macrophages. Proc.
Soc. Exp. Biol. Med. 199:65–67.
3. Askew, D. S., C. Bartholomew, and J. N. Ihle. 1993. Insertional mutagenesis
and the transformation of hematopoietic stem cells. Hematol. Pathol. 7:1–22.
4. Askew, D. S., C. Bartholomew, A. M. Buchberg, M. B. Valentine, N. A.
Jenkins, N. G. Copeland, and J. N. Ihle. 1991. His1 and His2: identification
and chromosomal mapping of two commonly rearranged sites of viral inte-
gration in myeloid leukemia. Oncogene 6:2041–2047.
5. Auch, D., and M. Reth. 1990. Exon trap cloning: using PCR to rapidly detect
and clone exons from genomic DNA. Nucleic Acids Res. 18:6743–6744.
6. Biegel, J. A., P. S. White, H. N. Marshall, M. Fujimori, E. H. Zackai, C. D.
Scher, G. M. Brodeur, and B. S. Emanuel. 1993. Constitutional 1p36 dele-
tion in a child with neuroblastoma. Am. J. Hum. Genet. 52:176–182.
7. Bloomfield, C. D., O. M. Garson, L. Volin, S. Knuntila, and A. de la
Chapelle. 1985. t(1;3)(p36,q21) in acute non-lymphoblastic leukemia: a new
cytogenetic-clinicopathologic association. Blood 66:1409–1413.
8. Bouaboula, M., M. Rinaldi, P. Carayon, C. Carillon, B. Delpech, D. Shire, G.
Le Fur, and P. Casellas. 1993. Cannabinoid-receptor expression in human
leukocytes. Eur. J. Biochem. 214:173–180.
9. Buchberg, A. M., H. G. Bedigian, N. A. Jenkins, and N. C. Copeland. 1990.
Evi2, a common integration site involved in murine myeloid leukemogenesis.
Mol. Cell. Biol. 10:4658–4666.
10. Buckler, A. J., D. D. Chang, S. L. Graw, J. D. Brook, D. A. Haber, P. A.
Sharp, and D. E. Housman. 1991. Exon amplification: a strategy to isolate
mammalian genes based on RNA splicing. Proc. Natl. Acad. Sci. USA
88:4005–4009.
11. Ceci, J. D., L. D. Siracusa, N. A. Jenkins, and N. G. Copeland. 1989. A
molecular genetic linkage map of mouse chromosome 4 including the local-
isation of several proto-oncogenes. Genomics 5:699–709.
12. Cheng, N. C., N. van Roy, A. Chan, M. Beitsma, A. Westerveld, F. Speleman,
and R. Versteeg. 1995. Deletion mapping in neuroblastoma cell lines sug-
gests two distinct tumor suppressor genes in the 1p35-36 region, only one of
which is associated with N-myc amplification. Oncogene 10:291–297.
13. Church, D. M., L. T. Banks, A. C. Rogers, S. L. Graw, D. E. Housman, J. F.
Gusella, and A. J. Buckler. 1993. Identification of human chromosome 9
specific genes using exon amplification. Hum. Mol. Genet. 2:1915.
14. Copeland, N. G., and N. A. Jenkins. 1991. Development and applications of
a molecular genetic linkage map of the mouse genome. Trends Genet.
7:113–118.
14a.Copeland, N. G., and N. A. Jenkins. Unpublished results.
15. Cuypers, H. T., G. Selten, W. Quint, M. Zijlstra, E. R. Maandag, W. Boelens,
P. van Wezenbeek, C. Melief, and A. Berns. 1984. Murine leukemia virus-
induced T-cell lymphomagenesis: integration of proviruses in a distinct chro-
mosomal region. Cell 37:141–150.
16. Davis, R. W., M. Thomas, J. Cameron, T. P. St. John, S. Scherer, and R. A.
Padgett. 1980. Rapid DNA isolation for enzymatic and hybridization anal-
ysis. Methods Enzymol. 65:404–411.
17. Dobner, T., I. Wolf, T. Emrich, and M. Lipp. 1992. Differentiation-specific
expression of a novel G protein-coupled receptor from Burkitt’s lymphoma.
Eur. J. Immunol. 22:2795–2799.
18. Duyk, G. M., S. Kim, R. M. Myers, and D. R. Cox. 1990. Exon trapping: a
genetic screen to identify candidate transcribed sequences in cloned mam-
malian genomic DNA. Proc. Natl. Acad. Sci. USA 87:8995–8999.
19. Feinberg, A. P., and B. Vogelstein. 1984. A technique for radiolabelling DNA
VOL. 71, 1997 Evi11, A NOVEL COMMON VIRUS INTEGRATION SITE 6803
restriction endonuclease fragments to high specific activity. Anal. Biochem.
132:6–13.
20. Fowler, M. L., H. Nakai, M. G. Byers, H. Fukushima, R. L. Eddy, W. M.
Henry, L. L. Haley, J. S. O’Brien, and T. B. Shows. 1986. Chromosome 1
localization of the human a-L-fucosidase structural gene with a homologous
site on chromosome 2. Cytogenet. Cell. Genet. 43:103–108.
21. Gerard, C. M., C. Mollereau, G. Vassart, and M. Parmentier. 1991. Molec-
ular cloning of a human cannabinoid receptor which is also expressed in
testis. Biochem. J. 279:129–134.
22. Green, E. L. 1981. Linkage, recombination and mapping, p. 77–113. In
Genetics and probability in animal breeding experiments. Oxford University
Press, New York, N.Y.
23. Hamaguchi, M., H. Sakamoto, H. Tsuruta, H. Sasaki, T. Muto, T. Sugimura,
and M. Terada. 1992. Establishment of a highly sensitive and specific exon-
trapping system. Proc. Natl. Acad. Sci. USA 89:9779–9783.
24. Holmes, K. L., E. Palaszynski, T. N. Frederickson, H. C. Morse III, and J. N.
Ihle. 1985. Correlation of cell-surface phenotype with the establishment of
IL-3 dependent cell lines from wild-mouse murine leukemia virus induced
neoplasms. Proc. Natl. Acad. Sci. USA 82:6687–6691.
25. Ihle, J. N., J. Keller, S. Oroszlan, L. E. Henderson, T. D. Copeland, F. Fitch,
M. B. Prystowsky, E. Goldwasser, J. W. Schrader, E. Palaszynski, M. Dy,
and B. Lebel. 1983. Demonstration of WEHI-3 growth factor activity, mast
cell growth factor activity, P-cell stimulating factor activity, colony stimulat-
ing factor activity and histamine producing cell stimulating factor activity.
J. Immunol. 131:282–287.
26. Ihle, J. N., A. Rein, and R. Mural. 1984. Immunological and virological
mechanisms in retrovirus-induced murine leukemogenesis. Viral Oncol. 4:
95–137.
27. Ihle, J. N., and D. Askew. 1989. Origins and properties of hematopoietic
growth factor-dependent cell lines. Int. J. Cell Cloning 7:68–91.
28. Jenkins, J. R., P. Ayton, T. Jones, S. L. Davies, D. L. Simmons, A. L. Harris,
D. Sheer, and I. D. Hickson. 1992. Isolation of cDNA clones encoding the
isoenzyme of human DNA topoisomerase II and localisation of the gene to
chromosome 3p24. Nucleic Acids Res. 20:5587–5592.
29. Jenkins, N. A., N. G. Copeland, B. A. Taylor, and B. K. Lee. 1982. Organi-
zation, distribution and stability of endogenous ecotropic murine leukemia
virus DNA sequences in chromosomes of Mus musculus. J. Virol. 43:26–36.
30. Jonkers, J., and A. Berns. 1996. Retroviral insertional mutagenesis as a
strategy to identify cancer genes. Biochim. Biophys. Acta 1287:29–57.
31. Justice, M. J., H. C. Morse III, N. A. Jenkins, and N. G. Copeland. 1994.
Identification of Evi3, a novel common site of retroviral integration in mouse
AKXD B-cell lymphomas. J. Virol. 68:1293–1300.
32. Kretz, K. A., D. Cripe, G. S. Carson, H. Fukushima, and J. S. O’Brien. 1992.
Structure and sequence of the human a-L-fucosidase gene and pseudogene.
Genomics 12:276–280.
33. Laureys, G., F. Speleman, G. Opdenakker, Y. Benoit, and J. Leroy. 1990.
Constitutional translocation t(1;17)(p36;q12-21) in a patient with neuroblas-
toma. Genes Chromosomes Cancer 2:252–254.
34. Liao, X., A. M. Buchberg, N. A. Jenkins, and N. G. Copeland. 1995. Evi5, a
common site of retroviral integration in AKXD T-cell lymphomas, maps
near Gfi1 on mouse chromosome 5. J. Virol. 69:7132–7137.
35. Matsuda, L. A., and T. I. Bonner. 1995. Molecular biology of the cannabi-
noid receptor, p. 117–143. In R. Pertwee (ed.), Cannabinoid receptors.
Academic Press, San Diego, Calif.
36. Morishita, K., D. S. Parker, M. L. Muscenski, N. A. Jenkins, N. G. Copeland,
and J. N. Ihle. 1988. Retroviral activation of a novel gene encoding a zincfinger
protein in IL-3-dependent myeloid leukemia cell lines. Cell 54:831–840.
37. Mucenski, M. L., B. A. Taylor, J. N. Ihle, J. W. Hartley, H. C. Morse III, N. A.
Jenkins, and N. G. Copeland. 1988. Identification of a common ecotropic
viral integration site, Evi1, in the DNA of AKXD murine myeloid tumors.
Mol. Cell. Biol. 8:301–308.
38. Mu¨ller, M. M., S. Ruppert, W. Schaffner, and P. Matthias. 1988. A cloned
octamer transcription factor stimulates transcription from lymphoid-specific
promoters. Nature 336:544–551.
39. Munro, S., K. L. Thomas, and M. Abu-Shaar. 1993. Molecular characteri-
sation of a peripheral receptor for cannabinoids. Nature 365:61–65.
40. Murison, G., C. B. H. Chubb, S. Maeda, M. A. Gemmell, and E. Huberman.
1987. Cannabinoids induce incomplete maturation of cultured human leu-
kemia cells. Proc. Natl. Acad. Sci. USA 84:5414–5418.
41. Nakamura, T., D. A. Largaepada, J. D. Shaughnessy, Jr., J. A. Jenkins, and
N. G. Copeland. 1996. Cooperative activation of Hoxa and Pbx1 related
genes in murine myloid leukemias. Nat. Genet. 12:149–153.
42. North, M. A., P. Sanseau, A. J. Buckler, D. Church, A. Jackson, K. Patel, J.
Trowsdale, and H. Lehrach. 1993. Efficiency and specificity of gene isolation
by exon amplification. Mamm. Genome 4:466–474.
43. Ross, P. C., R. A. Figler, M. H. Corjay, C. M. Barber, N. Adam, D. R. Harcus,
and K. R. Lynch. 1990. RTA, a candidate G protein-coupled receptor:
cloning, sequencing and tissue distribution. Proc. Natl. Acad. Sci. USA
87:3052–3056.
44. Sambrook, J., E. F. Fritsch, and T. Maniatis. 1989. Molecular cloning: a
laboratory manual, 2nd ed. Cold Spring Harbor Laboratory Press, Cold
Spring Harbor, N.Y.
45. Sanger, F., and A. R. Coulsen. 1975. A rapid method for determining se-
quences in DNA by primed synthesis with DNA polymerase. J. Mol. Biol.
13:441.
46. Severne, Y., S. Wieland, W. Schaffner, and S. Rusconi. 1988. Metal binding
‘finger’ structures in the glucocorticoid receptor defined by site-directed
mutagenesis. EMBO J. 7:2503–2508.
47. Shire, D., C. Carillon, M. Kaghad, B. Calandra, M. Rinaldi-Carmona, G. Le
Fur, D. Caput, and P. Ferrara. 1995. An aminoterminal variant of the central
cannabinoid receptor resulting from alternative splicing. J. Biol. Chem. 270:
3726–3731.
48. Shire, D., B. Calandra, M. Rinaldi-Carmona, D. Oustric, B. Pesse`gue, O.
Bonnin-Cabanne, G. Le Fur, D. Caput, and P. Ferrara. 1996. Molecular
cloning, expression and function of the murine CB2 peripheral cannabinoid
receptor. Biochim. Biophys. Acta 1307:132–136.
49. Suarez, H. G., D. Russo, R. Wickler, J. A. Du Villard, S. Filetti, B. Caillou,
and M. Schlumberger. 1995. Role of somatic genetic alterations of the
cAMP pathway in thyroid hyperfunctioning tumorigenesis. J. Cell. Biochem.
Suppl. 19A:44.
50. Van Lohuizen, M., and A. Berns. 1990. Tumorigenesis by slow-transforming
retroviruses—an update. Biochim. Biophys. Acta 1032:213–235.
51. Viguie, F., J. P. Marie, F. Poler, and A. Bernadeau. 1986. Three cases of
preleukemic myelodysplastic disorders with the same translocation t(1;3).
Cancer Genet. Cytogenet. 19:213–218.
52. Valk, P. J. M., S. Verbakel, Y. Vankan, S. Hol, B. Lo¨wenberg, and R. Delwel.
1996. Anandamide, a natural ligand for the peripheral cannabinoid receptor
is a novel synergistic growth factor for hematopoietic cells. Blood 88:339a.
53. Whitehead, I., H. Kirk, and R. Kay. 1995. Expression cloning of oncogenes
by retroviral transfer of cDNA libraries. Mol. Cell. Biol. 15:704–710.
54. Young, D., G. Waitches, C. Birchmeier, O. Fasano, and M. Wigler. 1986.
Isolation and characterization of a new cellular oncogene encoding a protein
with multiple potential transmembrane domains. Cell 45:711–719.
6804 VALK ET AL. J. VIROL.
